
<!DOCTYPE html>
	<html lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta name="description" content="">
    <meta name="author" content="">
    <link rel="shortcut icon" href="">
    <title>CCH Android Application</title>
	
    <!-- Bootstrap core CSS -->
    <link href="css/bootstrap.min.css" rel="stylesheet">

    <!-- Custom styles for this template 
	cchbasics - the main CSS file for non-bootstrap styling
	-->
    <link href="css/cchbasics.css" rel="stylesheet">
	<link rel="stylesheet" href="font-awesome/css/font-awesome.min.css">
	<script src='ckeditor\ckeditor.js'></script>

  </head>

  <body>
    <div class="container dropme">
		<div class="row">
			<div class="col-md-6 col-md-offset-3">
	<p><span style="font-size:16px"><em><strong>Intermittent Preventive Treatment (IPTp) with Sulfadoxine-Pyrimethamine (SP) for Malaria Prevention in Pregnant Women</strong>&nbsp;</em><img alt="" src="images/mosquito2.png" style="float:right;" /></span></p>

<p><strong><span style="color:#006400"><em style="font-size:13px; line-height:1.6">Target groups for IPTp using SP include:</em></span></strong></p>

<ul>
	<li>All pregnant women with no signs clinical malaria whose pregnancies are between 16-36 weeks of gestation</li>
	<li>Women with first or second pregnancies</li>
	<li>Adolescent and young pregnant women (10-24 years)</li>
	<li>Pregnant women with sickle cell disease</li>
	<li>Pregnant women with HIV infection and other immunocompromised states</li>
</ul>

<p><br />
<span style="color:#006400"><strong><em>Pregnant women with the following conditions should be exempted from using SP:</em></strong></span></p>

<ul>
	<li>Women in their 1<sup>st</sup> trimester of pregnancy (first 3 months)</li>
	<li>Women known to have Glucose-6-Phosphate Dehydrogenase (G6PD) enzyme deficiency, either full or partial defect</li>
	<li>Women known to have severe liver disease</li>
	<li>Women with unexplained recurrent jaundice</li>
	<li>Women who are known to be allergic to sulphur-containing drugs or pyrimethamine component</li>
	<li>Women who have received treatment with sulphur-based drugs, e.g. cotrimoxazole within 4 weeks of being seen at the clinic</li>
	<li>Women with HIV/AIDS who have been put on cotrimoxazole for opportunistic infections</li>
	<li>Women with pregnancy beyond 36 weeks (8 months) gestation</li>
	<li>Women breastfeeding</li>
</ul>

<p>&nbsp;</p>

<p><span style="color:#006400"><strong><em>Dosage of SP for IPTp:</em></strong></span></p>

<p>Single dose compromising 3 tablets of 500 mg sulfadoxine + 25 mg pyrimethamine taken with clean water after meals.&nbsp; Ensure pregnant clients eat before taking the drug.&nbsp; SP should be administered at:</p>

<ul>
	<li>1<sup>st</sup> dose at &gt;16 wks gestation</li>
	<li>2<sup>nd</sup> dose at least 4 weeks after 1<sup>st</sup> dose</li>
	<li>3<sup>rd</sup> dose at least 4 weeks after 2<sup>nd</sup> dose</li>
</ul>

<p><strong style="color:rgb(0, 100, 0); font-size:13px; line-height:1.6"><em>Counselling/Education on Use of SP</em></strong></p>

<ul>
	<li>All pregnant women should be educated and counselled on IPTp using SP on an individual basis prior to drug administration</li>
	<li>Women who receive SP should be educated on the potential adverse effects and what to do when these arise</li>
	<li>Women who refuse IPTp using SP for any reason should NOT be discriminated against, and should be counselled to use ITN</li>
</ul>

<p>&nbsp;</p>

<p>&nbsp;</p>
<button class='btn btn-lg btn-success' rel='external' onclick='window.location="index.html"'>Contents</button><br /><br />
			</div>
		</div>
	</div>
</body>
</html>